Kardium
Date | Investors | Amount | Round |
---|---|---|---|
N/A | Spinout | ||
N/A | $870k | Early VC | |
$80.0k | Grant | ||
$270k | Series D | ||
N/A | Late VC | ||
N/A | Growth Equity VC | ||
* | $115m | Growth Equity VC | |
CAD5.0m | Grant | ||
* | $104m | Late VC | |
Total Funding | $224m |
Recent News about Kardium
EditKardium is a medical device company specializing in the treatment of atrial fibrillation, a common heart rhythm disorder affecting over 37 million people globally. The company's core product, the Globe System, integrates high-definition anatomical and electrical mapping with radio frequency energy delivery to isolate pulmonary veins and ablate atrial tissue. This comprehensive solution is designed for cardiologists and electrophysiologists, offering a single device for multiple procedures. Kardium operates in the medical technology market, primarily targeting healthcare providers and institutions. The business model revolves around the sale of its advanced catheter systems and related services, generating revenue through direct sales and long-term contracts with medical facilities. The company is headquartered in greater Vancouver, Canada, and boasts a team of experts in medicine, engineering, and business.
Keywords: atrial fibrillation, catheter system, high-definition mapping, radio frequency ablation, pulmonary vein isolation, electrophysiology, cardiology, medical device, healthcare technology, Vancouver.